{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:10:02Z","timestamp":1749121802627,"version":"3.41.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Cabazitaxel (CAZ) has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel treatment. However, the impact of the number of prior androgen receptor pathway inhibitors (ARPIs) on CAZ efficacy remains unclear. This study aimed to analyze the effectiveness of CAZ based on the number of prior ARPIs administered before CAZ treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective review was conducted on mCRPC patients who received CAZ. The differences in CAZ efficacy based on the number of prior ARPIs were evaluated and prognostic factors for prostate-specific antigen (PSA) progression-free survival (PFS) and OS were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 59 patients were categorized into three groups: 12 patients with no prior ARPI, 26 with one prior ARPI, and 21 with two or more prior ARPIs. The median number of CAZ cycles and relative dose intensity were 5% and 60%, respectively. No significant differences were observed in PSA response or PFS among the three groups. Although OS from the first CAZ administration did not significantly differ among the groups, the OS from mCRPC diagnosis was shorter in the group with no prior ARPI. Multivariate analysis identified a time to mCRPC diagnosis of less than 11\u00a0months and low serum hemoglobin levels before CAZ administration as significant prognostic factors of poor OS following CAZ treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PSA response, PFS, and OS after CAZ administration did not significantly differ based on the number of prior ARPIs. CAZ efficacy appears consistent regardless of the number of prior ARPI sequences.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf034","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T10:16:46Z","timestamp":1740305806000},"page":"658-665","source":"Crossref","is-referenced-by-count":0,"title":["The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-0369","authenticated-orcid":false,"given":"Hisanori","family":"Taniguchi","sequence":"first","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Masuo","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University , 2-3-1 Shinmachi, Hirakata, Osaka 573-1191 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"2025060506415619600_ref1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"2025060506415619600_ref2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Bono","year":"2010","journal-title":"Lancet"},{"key":"2025060506415619600_ref3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref7","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025060506415619600_ref9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2025060506415619600_ref10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"key":"2025060506415619600_ref11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025060506415619600_ref12","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel As first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025060506415619600_ref13","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of Cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in Postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025060506415619600_ref14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CAD.0b013e32835a56bc","article-title":"Peg-filgrastim and cabazitaxel in prostate cancer patients","volume":"24","author":"di Lorenzo","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2025060506415619600_ref15","doi-asserted-by":"publisher","first-page":"7538647","DOI":"10.1155\/2017\/7538647","article-title":"Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received Cabazitaxel chemotherapy","volume":"2017","author":"Uemura","year":"2017","journal-title":"Biomed Res Int"},{"key":"2025060506415619600_ref16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/cas.13556","article-title":"Prognostic significance of grade 3\/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel","volume":"109","author":"Kosaka","year":"2018","journal-title":"Cancer Sci"},{"key":"2025060506415619600_ref17","doi-asserted-by":"publisher","first-page":"106468","DOI":"10.18632\/oncotarget.22474","article-title":"Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel","volume":"8","author":"Belderbos","year":"2017","journal-title":"Oncotarget"},{"key":"2025060506415619600_ref18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.21873\/invivo.12430","article-title":"Sarcopenia and visceral metastasis at Cabazitaxel initiation predict prognosis in patients with castration-resistant prostate cancer receiving Cabazitaxel chemotherapy","volume":"35","author":"Iwamoto","year":"2021","journal-title":"In Vivo"},{"key":"2025060506415619600_ref19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025060506415619600_ref20","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2025060506415619600_ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyaf034\/62054941\/hyaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyaf034\/62054941\/hyaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T10:42:04Z","timestamp":1749120124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/6\/658\/8030581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,23]]},"published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf034","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,23]]}}}